21.57
-1.95 (-8.29%)
| Penutupan Terdahulu | 23.52 |
| Buka | 23.86 |
| Jumlah Dagangan | 1,732,510 |
| Purata Dagangan (3B) | 2,901,409 |
| Modal Pasaran | 1,173,392,512 |
| Harga / Jualan (P/S) | 89.31 |
| Harga / Buku (P/B) | 14.20 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| Margin Operasi (TTM) | -329.90% |
| EPS Cair (TTM) | -1.37 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -7.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.98% |
| Nisbah Semasa (MRQ) | 6.55 |
| Aliran Tunai Operasi (OCF TTM) | -45.16 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -28.17 M |
| Pulangan Atas Aset (ROA TTM) | -35.24% |
| Pulangan Atas Ekuiti (ROE TTM) | -75.39% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Capricor Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.13 |
|
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 16.80% |
| % Dimiliki oleh Institusi | 41.06% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Black Diamond Financial, Llc | 30 Sep 2025 | 277,737 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 60.00 (HC Wainwright & Co., 178.16%) | Beli |
| Median | 50.00 (131.80%) | |
| Rendah | 13.00 (Roth Capital, -39.73%) | Beli |
| Purata | 45.33 (110.15%) | |
| Jumlah | 6 Beli | |
| Harga Purata @ Panggilan | 24.17 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| B. Riley Securities | 15 Dec 2025 | 50.00 (131.80%) | Beli | 26.55 |
| Piper Sandler | 10 Dec 2025 | 45.00 (108.62%) | Beli | 28.67 |
| Oppenheimer | 08 Dec 2025 | 54.00 (150.35%) | Beli | 28.56 |
| Maxim Group | 04 Dec 2025 | 50.00 (131.80%) | Beli | 25.40 |
| HC Wainwright & Co. | 03 Dec 2025 | 60.00 (178.16%) | Beli | 29.96 |
| Roth Capital | 12 Nov 2025 | 13.00 (-39.73%) | Beli | 5.87 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |